AR127243A1 - Compuestos, composiciones farmacéuticas y métodos para el tratamiento, prevención o manejo de trastornos hiperproliferativos - Google Patents

Compuestos, composiciones farmacéuticas y métodos para el tratamiento, prevención o manejo de trastornos hiperproliferativos

Info

Publication number
AR127243A1
AR127243A1 ARP220102678A ARP220102678A AR127243A1 AR 127243 A1 AR127243 A1 AR 127243A1 AR P220102678 A ARP220102678 A AR P220102678A AR P220102678 A ARP220102678 A AR P220102678A AR 127243 A1 AR127243 A1 AR 127243A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
compounds
stereoisomer
stereoisomers
compound
Prior art date
Application number
ARP220102678A
Other languages
English (en)
Inventor
Hans Lerchen
- Stelte-Ludwig Beatrix Georg
Mareike Wiedmann
Andreas Lerchen
Anne Rebstock
- Koebberling Johannes Sophie
Harvey Wong
Original Assignee
Vincerx Pharma Gmbh
Vincerx Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vincerx Pharma Gmbh, Vincerx Pharma Inc filed Critical Vincerx Pharma Gmbh
Publication of AR127243A1 publication Critical patent/AR127243A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento, se divulgan compuestos, composiciones farmacéuticas y métodos para el tratamiento, prevención o manejo de enfermedades y afecciones que incluyen trastornos hiperproliferativos tales como el cáncer en humanos y otros mamíferos. Los compuestos divulgados en el presente documento son profármacos de inhibidores de PTEFb, conjugados a una porción de unión a integrinas mediante conectores de escisión y/o espaciadores funcionales. Reivindicación 1: Un compuesto, o una sal farmacéuticamente aceptable de este, o un estereoisómero o mezcla de estereoisómeros de este, caracterizado porque comprende un inhibidor de PTEFb conjugado con uno o más aglutinantes de integrina a través de un conector. Reivindicación 41: Una composición farmacéutica caracterizada porque comprende un compuesto de una cualquiera de las reivindicaciones, una sal farmacéuticamente aceptable de este, un estereoisómero o una mezcla de estereoisómeros de este, y al menos un excipiente farmacéuticamente aceptable. Reivindicación 64: Un método para tratar una enfermedad o trastorno en un sujeto, caracterizado porque comprende administrar una cantidad terapéuticamente eficaz de un compuesto de una cualquiera de las reivindicaciones 1 a 40, una sal farmacéuticamente aceptable de este, un estereoisómero o una mezcla de estereoisómeros de este; o de la composición farmacéutica de la reivindicación 41, a cada paciente que necesite de este.
ARP220102678A 2021-10-04 2022-10-04 Compuestos, composiciones farmacéuticas y métodos para el tratamiento, prevención o manejo de trastornos hiperproliferativos AR127243A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163252116P 2021-10-04 2021-10-04

Publications (1)

Publication Number Publication Date
AR127243A1 true AR127243A1 (es) 2024-01-03

Family

ID=84329676

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102678A AR127243A1 (es) 2021-10-04 2022-10-04 Compuestos, composiciones farmacéuticas y métodos para el tratamiento, prevención o manejo de trastornos hiperproliferativos

Country Status (3)

Country Link
AR (1) AR127243A1 (es)
TW (1) TW202320863A (es)
WO (1) WO2023057812A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4229903A1 (de) 1992-09-08 1994-03-10 Bayer Ag Neue Acetale von Ketophosphamid und Alkylglycosiden
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
AU4412297A (en) 1996-09-10 1998-04-02 Burnham Institute, The Tumor homing molecules, conjugates derived therefrom, and methods of using sa me
EP1181055A2 (en) 1999-05-14 2002-02-27 Boehringer Ingelheim Pharmaceuticals Inc. Enzyme-activated anti-tumor prodrug compounds
EP1219305A1 (en) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units
EP1238678A1 (en) 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Enzyme-activated cytostatic conjugates with integrin ligands
EP3129387B1 (en) 2014-04-11 2019-06-26 Bayer Pharma Aktiengesellschaft Novel macrocyclic compounds
CA2990076A1 (en) 2015-06-22 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
BR112021008232A2 (pt) 2018-11-05 2021-08-03 Bayer Pharma Aktiengesellschaft conjugados citostáticos inovadores com ligantes de integrina

Also Published As

Publication number Publication date
WO2023057812A1 (en) 2023-04-13
TW202320863A (zh) 2023-06-01

Similar Documents

Publication Publication Date Title
JP5192485B2 (ja) 向精神性薬物またはｇａｂａアゴニストと有機酸とを含むコンジュゲート、ならびに疼痛および他のｃｎｓ障害を治療するためのそれらの使用
Wei et al. Dantrolene is cytoprotective in two models of neuronal cell death
CY1115046T1 (el) Καινουργια sirnas και μεθοδοι χρησης αυτων
EA201101507A1 (ru) Способы лечения солидных опухолей
EA201000157A1 (ru) Неосновные антагонисты рецептора меланин-концентрирующего гормона 1 типа и их применение
SV2011003912A (es) Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
EA201000808A1 (ru) Индольные соединения и способы лечения висцеральной боли
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
ECSP066457A (es) 5-arilpirimidinas como agentes anti-cancer
UY31800A (es) Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AR070299A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas
WO2008064107A3 (en) 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
GT200000184A (es) Composiciones para facilitar el crecimiento de la piel y metodos y articulos que la emplean.
RU2002111355A (ru) Производные 5бета-сапогенина и псевдосапогенина и их применение при лечении деменции
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
DOP2023000060A (es) Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención
MX2021010568A (es) Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades.
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
US20080214509A1 (en) Methods for enhancing the efficacy of vascular disrupting agents
AR096526A1 (es) Agentes citotóxicos para el tratamiento del cáncer
UY39516A (es) Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
ECSP034494A (es) Inhibidores novedosos de la farnesil proteino trasferasa como agentes antitumorales